Plain-English translation of NCT03890224 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether home non-invasive ventilation (NIV)—a breathing machine that helps you breathe better at night—can prevent hospital readmissions in people who have just recovered from a severe COPD flare-up. Researchers will compare four approaches: no home breathing support, basic home breathing support, closely monitored home breathing support with personalized settings, and on-demand breathing support. The study wants to see if this treatment, especially when carefully tailored and monitored remotely, can reduce hospitalizations and deaths.
COPD patients who experience severe breathing crises are at very high risk of returning to the hospital or dying within a year. While hospitals can provide temporary breathing support, patients need better long-term strategies at home to prevent these dangerous flare-ups and reduce the burden on healthcare systems.
You likely qualify if…
You likely don't qualify if…
After leaving the hospital, you will be randomly assigned to one of four groups: some participants will use a home breathing machine at night with remote monitoring that tracks how well the treatment is working, others will use basic home breathing support, some will use it only when needed, and a control group will receive standard hospital care only. You will be followed for about a year with regular check-ins to monitor your health, hospital visits, and quality of life. The study takes place across France, Spain, and Portugal.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
France
Sponsor
Clinact
Collaborators
Assistance Publique - Hôpitaux de Paris, Fondation du Souffle
Enrollment target
~400 participants
Started
July 2019
Primary completion
June 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Angèle Guilbot
Hôpital Pitié Salpêtrière-Charles Foix, Paris, France ,
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.